PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY

Hematological Oncology - United Kingdom
doi 10.1002/hon.47_2630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Ibrutinib Discontinuation in Waldenström Macroglobulinemia: Etiologies, Outcomes, and IgM Rebound

American Journal of Hematology
Hematology
2018English

Spotting the Elusive Siberian Tiger: Complete Response to Ibrutinib in a Patient With Waldenström Macroglobulinemia

American Journal of Hematology
Hematology
2018English

A Head-To-Head Phase 3 Study Comparing BGB-3111 and Ibrutinib in Patients With Waldenström Macroglobulinemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Evauation of Corcordance Between Patient Reported Outcomes (Pros) and Clinician Reported Outcomes (Cros) in Patients With Metastatic Brain Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Rituximab Intolerance in Patients With Waldenström Macroglobulinaemia

British Journal of Haematology
Hematology
2015English

Waldenström Macroglobulinemia

2020English

Profiling of Circulating Exosomal miRNAs in Patients With Waldenström Macroglobulinemia

PLoS ONE
Multidisciplinary
2018English

P3.15-08 Patient-Reported Outcomes (PROs) in Patients With Lung Resection: Open Versus Minimal Invasive Surgery

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Bruton's Tyrosine Kinase (Btk) Inhibitor BGB-3111 Demonstrates High Very Good Partial Response (Vgpr) Rate in Patients With Waldenström Macroglobulinemia (Wm)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy